首页> 外国专利> Hard gelatin capsules contg. nifedipine - as soln. in carrier not causing embrittlement

Hard gelatin capsules contg. nifedipine - as soln. in carrier not causing embrittlement

机译:硬明胶胶囊续。硝苯地平-如soln。在载体中不会引起脆化

摘要

Hard gelatin capsules contain nifedipine (I) dissolved in a water-soluble carrier (II) which does not embrittle the capsule on storage at room temp. (II) is an ethoxylated fatty acid ester, esp. a reaction prod. of 1 mole hydrogenated castor oil with 40 moles ethylene oxide, e.g. 'Cremphor' RH40 (RTM). The (I):(II) ratio is 1:10-70. The capsule shell material contains dyes, pigments or opacifiers esp. Ti02, Fe oxide or CaCO3. The soln. of (I) in (II) is introduced into the capsules and the capsule halves are sealed together with a strip of gelatin film. ADVANTAGE - Embrittlement problems associated with hygroscopic carriers such as polyethylene glycol are avoided (cf. DE3438830 , US4450877 ) Bioavailability and absorption of (I) are as good as with conventional capsules.
机译:硬明胶胶囊包含硝苯地平(I)溶于水溶性载体(II),该载体在室温下储存时不会使胶囊变脆。 (II)是乙氧基化的脂肪酸酯,特别是。反应产物。 1摩尔氢化蓖麻油与40摩尔环氧乙烷的混合物,例如“ Cremphor” RH40(RTM)。 (I):( II)的比例为1:10-70。胶囊壳材料包含染料,颜料或遮光剂,特别是。 TiO 2,氧化铁或CaCO 3。索恩将(II)中的(I)中的B 1引入胶囊中,并用一条明胶薄膜将两半胶囊密封在一起。优点-避免了与诸如聚乙二醇的吸湿性载体有关的脆化问题(参见DE3438830,US4450877)。(I)的生物利用度和吸收与常规胶囊一样好。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号